Navigation Links
OncoGenex Reports Financial Results for Fourth Quarter and Fiscal Year 2008 and Provides Outlook for 2009
Date:3/11/2009

recently submitted the protocol to the FDA for an SPA featuring pain palliation as the primary endpoint. Other Pipeline Highlights - OncoGenex completed patient enrollment in the portion of the Phase 1 clinical trial evaluating the safety of OGX-427 as a monotherapy in patients with solid tumors. - OncoGenex completed the Phase 1 clinical trial evaluating the safety of SN2310 in patients with advanced cancer. Corporate Highlights - Concurrent with the closing of the reverse takeover of Sonus, OncoGenex implemented an immediate workforce reduction of 49% in order to effectively utilize cash assets, while preserving the resources we believe are necessary to advance our priority clinical programs. The Company currently has 26 full-time employees. - In July 2008, OncoGenex increased its economic interest in the OGX- 011 development program and assumed full responsibility for the development of OGX-011 through an amended development agreement with Isis Pharmaceuticals, Inc. - In August 2008, the Company signed an exclusive in-licensing agreement with Bayer HealthCare LLC for development of a family of compounds known as caspase activators presently in preclinical research. As the caspase family of proteases plays essential roles in apoptosis, the caspase activators offer the potential for the development of therapies in the treatment of various cancers.

Conference Call Today at 4:30 p.m. ET

OncoGenex management will host a conference call at 4:30 p.m. Eastern Time today, Wednesday, March 11, 2009, to provide a business update and discuss the fourth quarter and fiscal year 2008 results. A live webcast and slide presentation will be available through the Events and Presentations Web page found in the Investor Relations section
'/>"/>

SOURCE OncoGenex Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related biology technology :

1. OncoGenex reports lead drug candidate OGX-011 achieved primary endpoint in Phase 2 Trial with second-line chemotherapy for prostate cancer
2. Sonus Pharmaceuticals and OncoGenex Technologies to Merge
3. OncoGenex to present at the Needham & Company 7th Annual Biotechnology & Medical Technology Conference
4. OncoGenex increases economic interest in lead cancer drug OGX-011
5. OncoGenex receives completed Special Protocol Assessment for primary registration study of lead drug candidate OGX-011
6. Sonus Pharmaceuticals and OncoGenex Technologies complete business combination; OncoGenex Pharmaceuticals to commence trading on NASDAQ Capital Market today
7. FDA Grants Fast Track Designation for OncoGenex Pharmaceuticals Lead Product Candidate OGX-011
8. OncoGenex Pharmaceuticals announces out-license of TOCOSOL Paclitaxel to Eagle Pharmaceuticals
9. OncoGenex To Present At The BioContact Quebec 2008 Annual Conference
10. OncoGenex Achieves Key Regulatory Milestone for Lead Product Candidate, OGX-011
11. OncoGenex Pharmaceuticals to Release Third Quarter Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/22/2014)... 2014 “Our nation's healthcare system ... national disgrace. Furthermore, every governmental and professional entity ... deplorable state of unorganized dysfunction shares in that ... merely serve as a device to use in ... failure(s) that have accumulated through the years leading ...
(Date:8/21/2014)... DESY scientists has observed tiny quantum vortices in cold ... journal Science that the exotic vortices arrange ... is the first time that the quantum vortices, which ... is known as superfluid helium, have been detected in ... Andrey Vilesov of the University of Southern California, one ...
(Date:8/21/2014)... , Aug. 21, 2014 Telomere ... of their Nutraceutical "TELO-20 for Dogs" with ... Telomere-lengthening supplement in the world for dogs. Telomeres ... every chromosome in the body. A wealth of ... experts in Telomere Science and Aging, including Nobel ...
(Date:8/21/2014)... Aug. 21, 2014 OTC Markets ... Inc., a biotechnology company, on its approval to ... traded on OTCQX®, the best marketplace for established ... Group. Logo - http://photos.prnewswire.com/prnh/20110118/MM31963LOGO ... successful execution of its growth strategy and achievement ...
Breaking Biology Technology:5 Great Mistakes in Healthcare and How to Fix Them by Dr. Ira Williams 2Scientists observe quantum vortices in cold helium droplets 2Telomere Biosciences Announces: TELO-20 for Dogs, the World's First Telomere-Lengthening Supplement for Dogs, to Promote Healthy Aging and Longevity 2Telomere Biosciences Announces: TELO-20 for Dogs, the World's First Telomere-Lengthening Supplement for Dogs, to Promote Healthy Aging and Longevity 3OTC Markets Group Congratulates Immune Pharmaceuticals on NASDAQ Listing 2
... Issues Have Been Resolved; Remaining Issues Pertain to ... of Third-party Manufacturing Facility Company Expects to ... LEXINGTON, Mass., Dec. 19 Indevus,Pharmaceuticals, Inc. (Nasdaq: ... letter from the U.S. Food and Drug Administration (FDA) ...
... Allows Accurate Marketing Claims Designed with Input from,Entire ... nation,s leading livestock,cloning companies announced today a tracking ... allow food companies to identify cloned animals,when they ... program was developed through extensive cooperative discussions,over the ...
... Announcement of a Tracking Program for,Cloned Livestock, ... by International Dairy Foods Association President and CEO ... new national registry to track cloned,livestock as a ... food,products from cloned animals. However, we strongly urge ...
Cached Biology Technology:Indevus Receives Non-Approvable Letter From FDA for VALSTAR(TM) 2Indevus Receives Non-Approvable Letter From FDA for VALSTAR(TM) 3Indevus Receives Non-Approvable Letter From FDA for VALSTAR(TM) 4Top U.S. Cloning Companies Announce New System to Track Cloned Livestock 2Statement of International Dairy Foods Association President and CEO Connie Tipton 2
(Date:8/21/2014)... eczema and other itchy, flaky maladies in humans has ... coral reefs and the extreme environments of arctic soils ... scientific journal PLOS Pathogens considers the diversity, ... Malassezia in light of new insights gained ... , University of Hawai,i at Mānoa scientist Anthony Amend ...
(Date:8/21/2014)... Israel Deaconess Medical Center (BIDMC ) are among the ... Minds 2014," a comprehensive list compiled by ... science metrics and research performance analysis. , ... performing and publishing work that their peers recognized as ... a Thomson Reuters statement. Researchers were identified based on ...
(Date:8/21/2014)... the water window? It consists of radiations in the ... by the water in biological tissues. New theoretical findings ... within the water window. These could be the basis ... of the biological samples or to be used in ... physical mechanism needed to efficiently generate the harmonic radiationswhich ...
Breaking Biology News(10 mins):From dandruff to deep sea vents, an ecologically hyper-diverse fungus 2BIDMC researchers named among 'the most influential scientific minds' 2BIDMC researchers named among 'the most influential scientific minds' 3Water window imaging opportunity 2
... In a brief paper in the journal Bioinformatics ... Web-based program called Spliceman for predicting whether genetic mutations ... potentially leading to disease. "Spliceman takes a set ... likely these single nucleotide variants alter splicing phenotypes," write ...
... in German . The Fukushima ... not over yet, neither in Japan nor in Germany. ... working groups that are still processing scientific findings for ... the energy turnaround in Germany by conducting research into ...
... and the Department of Fish and Game have completed an ... species of greatest concern. This first-of-its-kind study prioritizes which species ... in California. The study was published this week in the ... the study is that our unique approach is one that ...
Cached Biology News:Will a genetic mutation cause trouble? Ask Spliceman 21 year after Fukushima 21 year after Fukushima 3New study will help protect vulnerable birds from impacts of climate change 2
... Immunogen: Synthetic phosphopeptide corresponding to ... Ser603 residue of rat Synapsin ... synapsin I when phosphorylated at ... Rat (positive control: rat brain ...
MMP-20 Immunogen: Activated recombinant human MMP-2 Storage: -20 C, Avoid Freeze/Thaw Cycles...
karyopherin alpha2 (2G7)...
... PowerEase 500 Power Supply is ... It offers extensive programming capabilities ... custom methods for you to ... The simple intuitive PowerEase interface ...
Biology Products: